Literature DB >> 4416909

Withdrawal of allopurinol in patients with gout.

W Y Loebl, J T Scott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4416909      PMCID： PMC1006262          DOI： 10.1136/ard.33.4.304

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  8 in total

1.  Lesch-Nyhan syndrome. Management and treatment.

Authors:  J E Seegmiller
Journal:  Fed Proc       Date:  1968 Jul-Aug

2.  Microscopic studies on skeletal muscle in gout patients treated with allopurinol.

Authors:  R W Watts; J T Scott; R A Chalmers; L Bitensky; J Chayen
Journal:  Q J Med       Date:  1971-01

3.  Allopurinol and iron metabolism in man.

Authors:  J D Boyett; W R Vogler; V D Furtado; F H Schmidt
Journal:  Blood       Date:  1968-09       Impact factor: 22.113

4.  Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol.

Authors:  P R Band; D S Silverberg; J F Henderson; R A Ulan; R H Wensel; T K Banerjee; A S Little
Journal:  N Engl J Med       Date:  1970-08-13       Impact factor: 91.245

5.  Urinary xanthine stones--a rare complications of allopurinol therapy.

Authors:  M L Greene; W Y Fujimoto; J E Seegmiller
Journal:  N Engl J Med       Date:  1969-02-20       Impact factor: 91.245

6.  Effects of allopurinol on iron metabolism in man.

Authors:  B T Emmerson
Journal:  Ann Rheum Dis       Date:  1966-11       Impact factor: 19.103

7.  Allopurinol in treatment of gout.

Authors:  J T Scott; A P Hall; R Grahame
Journal:  Br Med J       Date:  1966-08-06

8.  Formation of nucleotides of (6-14C)allopurinol and (6-14C)oxipurinol in rat tissues and effects on uridine nucleotide pools.

Authors:  D J Nelson; C J Buggé; H C Krasny; G B Elion
Journal:  Biochem Pharmacol       Date:  1973-08-15       Impact factor: 5.858
  8 in total
  12 in total

Review 1.  Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?

Authors:  Ted R Mikuls; Kenneth G Saag
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

2.  Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.

Authors:  Eliseo Pascual; Francisca Sivera
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

Review 3.  Urate-lowering therapy: current options and future prospects for elderly patients with gout.

Authors:  Lisa K Stamp; Peter T Chapman
Journal:  Drugs Aging       Date:  2014-11       Impact factor: 3.923

4.  Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.

Authors:  Virginie Beslon; Perrine Moreau; Annabel Maruani; Hubert Maisonneuve; Bruno Giraudeau; Jean-Pascal Fournier
Journal:  J Gen Intern Med       Date:  2017-12-04       Impact factor: 5.128

5.  Single daily dose of allopurinol.

Authors:  I Brewis; R M Ellis; J T Scott
Journal:  Ann Rheum Dis       Date:  1975-06       Impact factor: 19.103

6.  Proceedings of a symposium on crystal-related arthropathies. 22 October and 23 October, 1982, Bristol Polytechnic, Bristol.

Authors: 
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

Review 7.  Long-term management of gout and hyperuricaemia.

Authors:  J T Scott
Journal:  Br Med J       Date:  1980-11-01

8.  Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.

Authors:  F Perez-Ruiz; A Alonso-Ruiz; M Calabozo; A Herrero-Beites; G García-Erauskin; E Ruiz-Lucea
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

9.  Withdrawal of longterm antihyperuricemic therapy in tophaceous gout.

Authors:  L F Gast
Journal:  Clin Rheumatol       Date:  1987-03       Impact factor: 2.980

Review 10.  Gout--current diagnosis and treatment.

Authors:  Anne-Kathrin Tausche; Tim L Jansen; Hans-Egbert Schröder; Stefan R Bornstein; Martin Aringer; Ulf Müller-Ladner
Journal:  Dtsch Arztebl Int       Date:  2009-08-24       Impact factor: 5.594
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.